Fiona Scott Morton
CPI Journal, 2013, vol. 9
This article lays out the economics of competition between branded and generic pharmaceuticals and its welfare consequences. I explain the logic behind so-called Ã¢â‚¬Å“pay-for-delayÃ¢â‚¬Â or Ã¢â‚¬Å“reverse paymentsÃ¢â‚¬Â in the context of the current IP environment where weak (probabilistic) patents are frequently granted by the PTO. Fiona Scott Morton (Yale University).
Keywords: Fiona Scott Morton; pay-for-delay; reverse payments; competition; antitrust (search for similar items in EconPapers)
JEL-codes: K21 (search for similar items in EconPapers)
References: Add references at CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
Requires login and subscription
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:cpi:cpijrn:9.2.2013:i=13221
Access Statistics for this article
More articles in CPI Journal from Competition Policy International
Bibliographic data for series maintained by Lindsay McSweeney ( this e-mail address is bad, please contact ).